Hemophilia and prophylaxis.
Ljung, Rolf LU
(2013)
In Pediatric Blood & Cancer
60(Suppl. S1).
p.23-26
- Abstract
- Clinical experience over decades and numerous retrospective and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless of whether the outcome is number of joint- or life-threatening bleeds or arthropathy optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the model. The optimal model should be to individualize prophylaxis taking into account the bleeding phenotype and the individual susceptibility to arthropathy and further develop monitoring by global coagulation assays and pharmacokinetic parameters. This review covers proof of concept of primary prophylaxis in children,... (More)
- Clinical experience over decades and numerous retrospective and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless of whether the outcome is number of joint- or life-threatening bleeds or arthropathy optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the model. The optimal model should be to individualize prophylaxis taking into account the bleeding phenotype and the individual susceptibility to arthropathy and further develop monitoring by global coagulation assays and pharmacokinetic parameters. This review covers proof of concept of primary prophylaxis in children, comparisons between prophylaxis and on demand treatment, and future trends of prophylactic treatment of hemophilia. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3160273
- author
- Ljung, Rolf
LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Pediatric Blood & Cancer
- volume
- 60
- issue
- Suppl. S1
- pages
- 23 - 26
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000311166600007
- pmid:23109472
- scopus:84869211465
- pmid:23109472
- ISSN
- 1545-5017
- DOI
- 10.1002/pbc.24340
- language
- English
- LU publication?
- yes
- id
- cc2af1a3-5089-4274-984b-553511b42f0b (old id 3160273)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23109472?dopt=Abstract
- date added to LUP
- 2016-04-04 08:55:19
- date last changed
- 2022-01-29 07:44:59
@article{cc2af1a3-5089-4274-984b-553511b42f0b,
abstract = {{Clinical experience over decades and numerous retrospective and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless of whether the outcome is number of joint- or life-threatening bleeds or arthropathy optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the model. The optimal model should be to individualize prophylaxis taking into account the bleeding phenotype and the individual susceptibility to arthropathy and further develop monitoring by global coagulation assays and pharmacokinetic parameters. This review covers proof of concept of primary prophylaxis in children, comparisons between prophylaxis and on demand treatment, and future trends of prophylactic treatment of hemophilia. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc.}},
author = {{Ljung, Rolf}},
issn = {{1545-5017}},
language = {{eng}},
number = {{Suppl. S1}},
pages = {{23--26}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Pediatric Blood & Cancer}},
title = {{Hemophilia and prophylaxis.}},
url = {{http://dx.doi.org/10.1002/pbc.24340}},
doi = {{10.1002/pbc.24340}},
volume = {{60}},
year = {{2013}},
}